Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes

Journal of Mass Spectrometry

Volumn 48, Issue 7, 2013, Pages 830-843

  Höppner, Sebastian ^a   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

doping; in vitro; metabolism; sport; SRT1720; SRT2104

Indexed keywords

COLLISION-INDUCED DISSOCIATION; IN-VITRO; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; MITOCHONDRIAL BIOGENESIS; MULTIPLE-REACTION MONITORING MODES; POSITIVE ELECTROSPRAY IONIZATION; SRT1720; SRT2104;

ACETYLATION; BIOMOLECULES; CHEMICAL ACTIVATION; DIAGNOSIS; DOPING (ADDITIVES); ELECTROSPRAY IONIZATION; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLITES; PHYSIOLOGY; SPORTS;

METABOLISM;

SIRTUIN 1; SIRTUIN 1720; UNCLASSIFIED DRUG;

ARTICLE; DOPING; ELECTROSPRAY; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; URINALYSIS;

DOPING; IN VITRO; METABOLISM; SPORT; SRT1720; SRT2104;

CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; ENZYME ACTIVATION; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; LIMIT OF DETECTION; LIQUID-LIQUID EXTRACTION; MALE; MICROSOMES, LIVER; REPRODUCIBILITY OF RESULTS; SIRTUIN 1; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

MUS;

EID: 84879895891     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.3227     Document Type: Article

References (48)

1. K. T. Howitz, K. J. Bitterman, H. Y. Cohen, D. W. Lamming, S. Lavu, J. G. Wood, R. E. Zipkin, P. Chung, A. Kisielewski, L. L. Zhang, B. Scherer, D. A. Sinclair,. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191.
2. S. J. Lin, P. A. Defossez, L. Guarente,. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000, 289, 2126.
3. T. M. Bass, D. Weinkove, K. Houthoofd, D. Gems, L. Partridge,. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 2007, 128, 546.
4. S. Michan, D. Sinclair,. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404, 1.
5. M. C. Haigis, D. A. Sinclair,. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5, 253.
6. B. C. Smith, W. C. Hallows, J. M. Denu,. Mechanisms and molecular probes of sirtuins. Chem. Biol. 2008, 15, 1002.
7. J. P. Silva, C. Wahlestedt,. Role of Sirtuin 1 in metabolic regulation. Drug Discov. Today 2010, 15, 781.
8. K. J. Menzies, D. A. Hood,. The role of SirT1 in muscle mitochondrial turnover. Mitochondrion 2012, 12, 5.
9. P. S. Pardo, A. M. Boriek,. The physiological roles of Sirt1 in skeletal muscle. Aging (Albany NY) 2011, 3, 430.
10. B. Gurd, C. Williams,. Skeletal muscle SIRT1 and the genetics of metabolic health: therapeutic activation by pharmaceuticals and exercise. Appl. Clin. Genet. 2012, 5, 81.
11. D. N. Gross, A. P. van den Heuvel, M. J. Birnbaum,. The role of FoxO in the regulation of metabolism. Oncogene 2008, 27, 2320.
12. A. Brunet, L. B. Sweeney, J. F. Sturgill, K. F. Chua, P. L. Greer, Y. Lin, H. Tran, S. E. Ross, R. Mostoslavsky, H. Y. Cohen, L. S. Hu, H. L. Cheng, M. P. Jedrychowski, S. P. Gygi, D. A. Sinclair, F. W. Alt, M. E. Greenberg,. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303, 2011.
13. C. Canto, Z. Gerhart-Hines, J. N. Feige, M. Lagouge, L. Noriega, J. C. Milne, P. J. Elliott, P. Puigserver, J. Auwerx,. AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature 2009, 458, 1056.
14. C. Canto, J. Auwerx,. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20, 98.
15. Z. Gerhart-Hines, J. T. Rodgers, O. Bare, C. Lerin, S. H. Kim, R. Mostoslavsky, F. W. Alt, Z. Wu, P. Puigserver,. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007, 26, 1913.
16. J. Lin, H. Wu, P. T. Tarr, C. Y. Zhang, Z. Wu, O. Boss, L. F. Michael, P. Puigserver, E. Isotani, E. N. Olson, B. B. Lowell, R. Bassel-Duby, B. M. Spiegelman,. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418, 797.
17. J. T. Rodgers, C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, P. Puigserver,. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434, 113.
18. P. Li, W. Fan, J. Xu, M. Lu, H. Yamamoto, J. Auwerx, D. D. Sears, S. Talukdar, D. Oh, A. Chen, G. Bandyopadhyay, M. Scadeng, J. M. Ofrecio, S. Nalbandian, J. M. Olefsky,. Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 2011, 147, 815.
19. F. Picard, M. Kurtev, N. Chung, A. Topark-Ngarm, T. Senawong, R. Machado De Oliveira, M. Leid, M. W. McBurney, L. Guarente,. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429, 771.
20. C. Handschin, B. M. Spiegelman,. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27, 728.
21. J. C. Milne, P. D. Lambert, S. Schenk, D. P. Carney, J. J. Smith, D. J. Gagne, L. Jin, O. Boss, R. B. Perni, C. B. Vu, J. E. Bemis, R. Xie, J. S. Disch, P. Y. Ng, J. J. Nunes, A. V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D. A. Sinclair, J. M. Olefsky, M. R. Jirousek, P. J. Elliott, C. H. Westphal,. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712.
22. J. N. Feige, M. Lagouge, C. Canto, A. Strehle, S. M. Houten, J. C. Milne, P. D. Lambert, C. Mataki, P. J. Elliott, J. Auwerx,. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8, 347.
23. B. P. Hubbard, A. P. Gomes, H. Dai, J. Li, A. W. Case, T. Considine, T. V. Riera, J. E. Lee, S. Y. E, D. W. Lamming, B. L. Pentelute, E. R. Schuman, L. A. Stevens, A. J. Ling, S. M. Armour, S. Michan, H. Zhao, Y. Jiang, S. M. Sweitzer, C. A. Blum, J. S. Disch, P. Y. Ng, K. T. Howitz, A. P. Rolo, Y. Hamuro, J. Moss, R. B. Perni, J. L. Ellis, G. P. Vlasuk, D. A. Sinclair,. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339, 1216.
24. K. Huber, G. Superti-Furga,. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg. Med. Chem. 2011, 19, 3616.
25. C. A. Blum, J. L. Ellis, C. Loh, P. Y. Ng, R. B. Perni, R. L. Stein,. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J. Med. Chem. 2011, 54, 417.
26. Y. Qi, M. L. Davis, E. O. Lainez, A. M. Cote, M. O. Johnson, D. J. Gagne, G. P. Vlasuk, J. L. Ellis, V. Suri,. SRT2104, a Novel Small Molecule SIRT1 Activator Ameliorates Insulin Resistance and Promotes Glucose Utilization Measured under a Hyperinsulinemic-Euglycemic Clamp by Enhancing Both Glycolysis and Carbohydrate Oxidation in Mice Fed a High Fat Diet. 2011. http://www.sirtrispharma.com/pdfs/ADA-11-Poster-Qi-et-al.pdf.
27. V. Suri, Y. Qi, M. Davis, A. Cote, E. Lainez, M. Johnson, M. Hirsch, D. Gagne, J. Ellis, G. Mathai,. Metabolomic Analysis Reveals Profound Impact of SIRT1 Activators on Carbohydrate and Lipid Oxidation in Multiple Tissues. 2011. http://www.sirtrispharma.com/pdfs/Cell-Aging-Poster-11-Suri-et-al.pdf.
28. T. Yoshizaki, S. Schenk, T. Imamura, J. L. Babendure, N. Sonoda, E. J. Bae, D. Y. Oh, M. Lu, J. C. Milne, C. Westphal, G. Bandyopadhyay, J. M. Olefsky,. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 2010, 298, E419.
29. L. M. Howells, D. P. Berry, P. J. Elliott, E. W. Jacobson, E. Hoffmann, B. Hegarty, K. Brown, W. P. Steward, A. J. Gescher,. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila.) 2011, 4, 1419.
30. J. M. Villalba, R. de Cabo, F. J. Alcain,. A patent review of sirtuin activators: an update. Expert Opin. Ther. Pat. 2012, 22, 355.
31. D. H. Lee,. Sirt1 as a New Therapeutic Target in Metabolic and Age-Related Diseases. Chonnam Med. J. 2010, 46, 67.
32. C. B. Vu, J. E. Bemis, J. S. Disch, P. Y. Ng, J. J. Nunes, J. C. Milne, D. P. Carney, A. V. Lynch, J. J. Smith, S. Lavu, P. D. Lambert, D. J. Gagne, M. R. Jirousek, S. Schenk, J. M. Olefsky, R. B. Perni,. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem. 2009, 52, 1275.
33. V. M. Nayagam, X. Wang, Y. C. Tan, A. Poulsen, K. C. Goh, T. Ng, H. Wang, H. Y. Song, B. Ni, M. Entzeroth, W. Stunkel,. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 2006, 11, 959.
34. J. L. Ellis, D. J. Gagne, V. Suri, J. M. Cermak, G. D. Lyng, L. P. Guarente, G. P. Vlasuk,. SRT2104, a novel and selective small molecule SIRT1 activator, inhabits DSS-iduced colitis in a SIRT1-dependent manner. 2011. http://www.sirtrispharma.com/pdfs/WIC-11-Poster-Ellis-et-al.pdf.
35. E. Hoffmann, J. Wald, S. Lavu, J. Roberts, C. Beaumont, J. Haddad, P. Elliott, C. Westphal, E. Jacobson,. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol. 2013, 75, 186.
36. V. Libri, A. P. Brown, G. Gambarota, J. Haddad, G. S. Shields, H. Dawes, D. J. Pinato, E. Hoffman, P. J. Elliot, G. P. Vlasuk, E. Jacobson, M. R. Wilkins, P. M. Matthews,. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2012, 7, e51395.
37. S. Höppner, W. Schänzer, M. Thevis,. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes. Rapid Commun. Mass Spectrom. 2013, 27, 35.
38. A. Thomas, S. Guddat, M. Kohler, O. Krug, W. Schänzer, M. Petrou, M. Thevis,. Comprehensive plasma-screening for known and unknown substances in doping controls. Rapid Commun. Mass Spectrom. 2010, 24, 1124.
39. T. Kuuranne, A. Leinonen, W. Schänzer, M. Kamber, R. Kostiainen, M. Thevis,. Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metab. Dispos. 2008, 36, 571.
40. P. Baranczewski, A. Stanczak, A. Kautiainen, P. Sandin, P. O. Edlund,. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol. Rep. 2006, 58, 341.
41. P. Baranczewski, A. Stanczak, K. Sundberg, R. Svensson, A. Wallin, J. Jansson, P. Garberg, H. Postlind,. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol. Rep. 2006, 58, 453.
42. S. Beuck, W. Schänzer, M. Thevis,. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes. J. Mass Spectrom. 2011, 46, 112.
43. International Conference of Harmonisation. 2004. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/ Q2-R1/Step4/Q2-R1-Guideline.pdf.
44. S. Kromidas,. Validierung in der Analytik, Wiley-VCH: Weinheim, 2011.
45. B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng,. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019.
46. B. Paizs, S. Suhai,. Fragmentation pathways of protonated peptides. Mass Spectrom. Rev. 2005, 24, 508.
47. F. Falvo, L. Fiebig, F. Dreiocker, R. Wang, P. B. Armentrout, M. Schäfer,. Fragmentation reactions of thiourea- and urea-compounds examined by tandem MS-, energy-resolved CID experiments, and theory. Int. J. Mass Spectrom. 2012, 330-332, 124.
48. S. Guddat, E. Solymos, A. Orlovius, A. Thomas, G. Sigmund, H. Geyer, M. Thevis, W. Schänzer,. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test. Anal. 2011, 3, 836.